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Abstract. The aims of this study to analyze the potential of daidzein compounds as selective 
estrogen receptor modulators (SERMs) compared with 17-β estradiol. SERMs is a compound that 
can be used as a anticancer of breast cancer. The process of analysis is done computation, that is 
molecular docking. The research was conducted at Data Processing Laboratory of Department of 
Biology Faculty of Science and Technology, State Islamic University of Sunan Gunung Djati 
Bandung in December 2017 until February 2018. The result of analysis showed that daidzein 
compounds have excellent potential as SERMs. This is indicated by the very low energy value of 
binding affinity of Deidzein (-9.4 kcal / mol) compared to17-β estradiol (-8.9 kcal / mol). The 
smallest of energy binding affinity value indicates a very high binding ability. 
1 Introduction 
Breast cancer is a disease with the highest mortality rate, 
an Indonesian women. There were approximately 48,998 
cases occurring with a mortality rate of 21.4% [1]. 
Factors that play an important role in the development of 
breast cancer are estrogen and estrogen alpha receptors 
[2]. RE-α is responsible for controlling transcription of 
nuclear DNA that is considered an important component 
of breast cancer signal network and appears as a novel 
biomarker of this disease [3].  
Treatment strategies are largely focused on blocking 
signals passing through RE-α [4]. Clinical therapy has 
been using drugs that act as SERMs (Selective Estrogen 
Receptor Modulators). SERMs compounds are 
compounds capable of competing with endogenous 
estrogens to modulate the activity of estrogen receptors 
[5]. Types of SERMs that have been known and used in 
clinical use include tamoxifen and raloxifen that act 
directly as ER-α antagonists [6]. But in its use cause 
various side effects such as cataracts, stroke, uterine 
cancer and blood clots [7]. An approach taken to limit 
the side effects of treatment therapy is by using drugs 
that can work as SERMs and are sourced from natural 
ingredients.   
One type of drug candidate that is predicted to act as 
a SERMs compound is daidzein (7,4'-dihydroxy 
isoflavones). Daidzein belong to phytoestrogens and 
potentially become a compound anticancer breast, 
daidzein found in soybean [8]. Previous in vitro studies 
have shown that daidzein is able to inhibit the 
proliferation of MCF-7 breast cancer cell cultures, and is 
associated with expression of estrogen alpha receptors 
(RE-α) [9]. Based on epidemiological studies, 
consumption of soy isoflavones especially daidzein has a 
compreventive benefit to breast cancer [10]. 
The present study focused on silico analysis of 
daidzein to confirm, evaluate, and learn more about 
daidzein's ability as a ligand in RE-a. This study was 
conducted by tethering daidzein molecules to RE-α. In-
silico testing is used as a connection between one stage 
to the next with a short time, accurate results and low 
cost to determine the effectiveness of the compound 
[11]. The purpose of this study is to determine the ability 
of daidzein as a competitor and how daidzein 
conformation on RE-α in silico. 
2 Material and Methods 
Three-dimensional Receptor Estrogen (RE)-α structure 
downloaded from the Protein Data Bank website (GDP, 
coded 1SJ0) and a three-dimensional structure of 
daidzein compound downloaded from zinc.docking.org 
with the zinc code: 18847034 and 17-β Estradiol with 
zinc code: 13520815.  
 The device used is the ASUS A43S series laptop 
hardware with Intel Core i3-2350 M @ 2.30 GHz 
processor and Windows 7 ultimate 32-bit operating 
system. Then the software used for molecular docking is 
Accelrys Discovery Studio 4.5 for material preparation 
and conformational visualization between small 
molecules and macromolecule systems, PyRx (Virtual 
screening tool) for molecular tethering. Here are the 
stepsn 
1. Preparation: The complex structure of RE-α GDP 
(1SJ0) opens on the Accelrys D.S 4.5 software then 
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between receptors and separated crystallographic 
ligands. 
2. Validation Method: At this step the optimization of 
RE-α by determining the grid box binding site 
(binding site) using AutoDock Vina-PyRx software 
with Grid Center x = 31,6846, y = -1,1900 and z = 
25,3418 which has dimension 25 x 25 x 25 Å, 
Subsequently a recombination of receptor and 
crystallographic ligands is performed. It then divides 
the poses to compare the location of the 
crystallographic ligand and the result of retouching 
on the receptor using Accelrys D. S. 4.5 software. 
Validation parameters include RMSD <2 Å. The 
smaller RMSD shows the position of the retarded 
ligand which is closer to the position of the 
crystallographic ligand [12].  
3. Molecular Mooring Simulation: Molecular 
tethering is done with the Pyrenx assisted Vina 
AutoDock program. Macromolecule and ligand files 
are then opened in this program. Macromolecule 
and ligand files in * .pdb format are then converted 
into * .pdbqt format via the PyRx assisted Vina 
AutoDock program. The .pdb format in the ligand 
and receptor shows no charge on the molecule, 
whereas the .pdbqt format shows a partial charge on 
each atom [13]. Then tethered using a Grid box 
determined by the position of the crystallographic 
ligand on the alpha estrogen receptor binding site at 
the validation stage. The result of this tethering will 
result in the affinity binding value of each tested 
ligand. The parameters used are the lowest affinity 
binding values of each ligand which will proceed to 
the next stage of conformational visualization. 
4. Visualization of Conformation: The 
conformational visualization is performed on the 
Accelrys D. S. 4.5 device by opening the receptor 
structure as a macromolecule which is then tethered 
with each of the lowest energy ligands to see the 
conformation and interaction with the amino acid 
residues formed. 
5. Data Analysis: The simulation results of molecular 
tethering were analyzed for conformation and 
interaction using Accelrys D. S. 4.5 software taking 
into account the types of interactions and amino acid 
residues involved. 
3 Result and Discussion 
The daizein tethering process carried out against a 
receptor protein in the form of the RE-α complex with 
the 1SJ0 code, chosen for being validated by the GDP 
site as a non-mutant receptor with a resolution <2 Å. The 
result of the preparation is the lumbar receptor beam by 
removing the water group. Prior to molecular tethering, a 
method validation is performed. This stage aims to 
determine the validity of the software and determine the 
boundaries of the search area of the ligand binding site 
on RE-α. The parameters used are RMSD and affinity 
binding, RMSD <2 Å and affinity binding values are 
parameters to maximize software work for the next step 
[11]. Validation of molecular tethering is done by 
recombination using Pyrenx-assisted AutoDock Vina. 
Validation was performed on the active side of the co-
crystal ligand to the crystallographic ligand. The result 
of validation method can be seen in Table 1. 
 
Table 1. Results of Crystallographic and Co-Crystal Ligand 
Recovery Against RE-α. 
No. Ligand 
Tethered Result 
Binding Affinity 
(kckal/mol) 
RMSD 
(Å) 
1. Crystallographic  -11,3 - 
2. Result of Co-
Crystal tethered 
-11,3 1,38 
 
Table 1 shows the RMSD value of the recombinant 
ligand that is 1.38 Å, meaning the value is less than 2 Å. 
This value implies that tethering can be accepted because 
the value is still <2 Å, the smaller the deviation value, 
the more accurate the calculation [11]. The affiinity 
binding value of the crystallographic ligand and the 
result of tethering have the same value of -11.3 kcal / 
mol, meaning no change in the value of binding affinity. 
Meanwhile, the poses of the crystallographic ligand and 
the results of the tethering are visualized by the Fig. 1. 
 
 
 
Fig. 1. Results of tethered crystallographic ligands (yellow) 
Compared to Co-Crystal Ligands Optimized Results (red) 
Using Accelrys Software D.S 4.5. 
 
Fig. 1 shows the position of the crystallographic 
ligand and the recovered ligand residing on the same 
active side of RE-α. This means that the positions of 
atoms in the recovered ligand do not differ greatly with 
the position on the crystallographic ligands [14,15].  
These results indicate that 1SJ0 receptors can be used for 
further tethering. 
Furthermore, a daidzein tethering simulation was 
performed as a ligand candidate on alpha estrogen 
receptor using a predefined grid box on the validation 
result. The more stable the interaction of the ligand with 
the protein is seen with the lower free energy shown by 
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the affinity binding value. Here are the lowest free 
energy results obtained from tethering: 
 
Table 2. Comparison of Affinity Balance Value (kcal /mol) 
Daidzein and 17-β Estradiol. 
No Ligan Name Binding Affnity (kkal/mol) 
1. Daidzein -9,4 
2. 17-β Estradiol  -8,9 
 
Table 2 shows the affinity binding value of daidzein 
compound ie -9.4 kcal / mol lower than endogenous 
ligand (17-β Estradiol) -8.9 kcal / mol. Lower affinity 
binding values indicate that the ligand may interact 
spontaneously with ER-α without requiring large 
bonding energies to bind, so that the ligand is suspected 
to have an estrogenic potential [11]. With lower affinity 
binding values than the control ligand predicted daidzein 
is able to inhibit the process of receiving signals at 
estrogen alpha receptors. 
The lowest affinity binding values of daidzein and 
control ligand were then visualized in conformation to 
estrogen alpha receptors. The results of daidzein 
conformation and 17 -β-estradiol RE-α can see at Fig. 2.  
 
 
Fig. 2. Molecular Interactions between Daidzein Compounds 
(purple color), and 17-β Estradiol (red color) with Estrogen 
Alfa Receptor. 
 
The conformational analysis of Fig. 2 shows that the 
daidzein ligand and 17-β Estradiol are on the same active 
RE-α side. Thus daidzein compounds are predicted to 
have the ability to block the action of signaling from 
endogenous ligands to estrogen alpha receptors. Further 
interaction analysis results are done by taking into 
account the non-bond interaction consisting of hydrogen 
bonding, hydrophobic interaction and electrostatic 
interaction. The types of interactions that occur between 
daidzein and RE-α can be seen in Fig. 3. 
 
 
Fig. 3. Amino Acid Residue Interactions Tied to Daidzein 
Compounds on RE-α. 
 
Fig. 3 shows the conformation of daidzein residing 
on the binding site of RE-α with the amino acid residues 
involved. The types of amino acid residues involved are 
PHE404, LEU391, ALA350, ILE424, GLY521, 
LEU525, HIS524, MET421 and LEU346. These amino 
acid residues are taken into account in determining the 
type of interaction to be formed. The types of 
interactions are presented in Table 3. 
Table 3 shows the molecular interaction of daidzein 
to RE-α in the 5 Å range range. It is predicted that there 
are 3 hydrogen bonds and 7 hydrophobic interactions 
(Table 3). The amino acid residues involved in forming 
conventional hydrogen bonds formed between daidzein 
and RE-α are HIS524, PHE404 and GLY521 with a 
spacing of 2.13 Å, 2.32 Å and 2.37 Å respectively. Then 
the hydrophobic interactions involving Pi-alkyl groups 
formed between daidzein and RE-α residues are 
ALA350, ILE424, LEU525, LEU391 and LEU346 with 
a spacing of 4.78 Å, 4.82 Å, 5.02 Å, 5.20 Å and 5.23 Å. 
Other interactions involving Pi-Pi and Pi-Sulfur are 
formed by PHE404 residues at a distance of 4.71 Å and 
MET421 at a distance of 5.12 Å. The amount of 
hydrogen bonding and hydrophobic interaction involved 
and the distance from the bonds that will affect the value 
of free energy, the more interaction and closer the 
bonding distance that occurs in molecular tethering the 
lower the value of free energy obtained and vice versa. 
The low distance interval and strong effect on free 
energy for molecular blocking is between 2.5 - 3 Å [11]. 
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Table 3. Non-Bond Interaction between Daidzein and Estrogen 
Alfa Receptor (RE-α). 
Amino Acid 
Residues 
Distance 
(Å) Type of Interaction 
HIS524 2,13 Hydrogen Bond 
PHE404 2,32 Hydrogen Bond 
GLY521 2,37 Hydrogen Bond 
PHE404  4,71  Hydrophobic 
ALA350 4,78 Hydrophobic 
ILE424 4,82 Hydrophobic 
LEU525 5,02 Hydrophobic 
MET421 5,12 Etc. 
LEU391 5,20 Hydrophobic 
LEU346 5,23 Hydrophobic 
 
The hydrogen bond is a molecular bond between H 
atoms with an electronegative atom such as N, O and F. 
The role of hydrogen bonds is very significant in the 
structure of proteins because the structural stability of a 
protein is influenced by hydrogen bonds. While the 
residue involved in hydrophobic interaction is a residue 
of nonpolar amino acid. The hydrophobic effect is 
usually defined as a reduction in one of the relatively 
unfavorable interactions that occur between water and 
nonpolar atoms [16]. Further conformational analysis 
between 17-β Estradiol with RE-α can be seen in Fig. 4. 
 
 
Fig. 4. Amino Acid Residue Interactions Tied to 17-β Estradiol 
Compounds on RE-α. 
 
Fig. 4 shows the conformation of 17-β Estradiol 
located on the binding site of RE-α with the amino acid 
residues involved are LEU391, MET388, LEU387, 
GLU353, ALA350, LEU346, LEU525, MET343, 
MET421 and PHE404. Then the type of interaction that 
is formed is presented in Table 4.  
 
Table 4. Non-Bond Interactions between 17-β Estradiol and 
Estrogen Alfa Receptor (RE-α). 
Amino Acid Residues Distance (Å) Type of Interaction 
GLU353 2,87 Hydrogen Bond 
LEU387 2,91 Hydrogen Bond 
LEU387 3,89 Hydrophobic 
ALA350 4,10 Hydrophobic 
MET421 4,38 Hydrophobic 
LEU391 4,69 Hydrophobic 
LEU346 4,70 Hydrophobic 
PHE404 5,02 Hydrophobic 
MET388 5,03 Hydrophobic 
LEU387 5,05 Hydrophobic 
LEU525 5,15 Hydrophobic 
LEU346 5,20 Hydrophobic 
ALA350 5,24 Hydrophobic 
PHE425 5,29 Hydrophobic 
MET343 5,45 Hydrophobic 
 
Table 4 shows the 17-β Estradiol molecular 
interaction with RE-α in the 5 Å range range. It is 
predicted that there are 2 hydrogen bonds and 13 
hydrophobic interactions (Table 4). The amino acid 
residues involved in forming conventional hydrogen 
bonds formed between 17-β Estradiol and RE-α are 
GLU353 with a distance of 2.87 Å and LEU387 with a 
distance of 2.91 Å. Then a hydrophobic interaction 
involving Pi-Sigma is formed between 17-β Estradiol 
and RE-α with the residue involved LEU387 with a 
distance of 3.89 Å. Interactions involving alkyl groups 
are ALANIN350, METIONIN421, LEUSIN346, 
METIONIN388, LEUSIN387, LEUSIN525, 
LEUSIN346, and METIONIN343 with a spacing of 4.10 
Å, 4.38 Å, 4.70 Å, 5.03 Å, 5.05, respectively Å, 5.15 Å, 
5.20 Å, and 5.45 Å. Other interactions involving Pi-
Alkyl are PHE404, PHE425, ALA350 and LEU391 with 
a spacing of 5.02 Å, 5.29 Å, 5,24 Å and 4,69 Å 
respectively. 
According to Table 4, 17-β Estradiol has more 
hydrophobic bonds, hydrophobically bound ligands with 
receptors are predicted to produce loose bonds when 
competing with ligands that have more hydrogen bonds. 
In addition, too hydrophobic molecules cause the bond 
selectivity to target receptors to be reduced [17]. 
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Based on the results of the analysis of silico daidzein 
including compounds that act as Selective Estrogen 
Receptor Modulators (SERMs) based on affective 
binding values and interactions, daidzein is predicted to 
compete and prevent agonist binding between 
endogenous ligand (17-β Estradiol) and RE-α through 
reversible competitive inhibition and making it more 
selective against estrogen alpha receptors [18]. 
4 Conclusion 
Daidzein memiliki energi afinitas yang sangat rendah 
yaitu -9,4 kkal/mol dibanding dengan dibanding 17-β 
estradiol yaitu -8,9 kkal/mol sehingga Deidzein 
berpotensi sebagai modulator selektif reseptor estrogen. 
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